{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:25:30Z","timestamp":1786879530508,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurol.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:42:55Z","timestamp":1780519375000},"page":"590-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current management and treatment of patients with myasthenia gravis in France: A survey of the neurologist's perspective"],"prefix":"10.1016","volume":"182","author":[{"given":"P.","family":"Cintas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Demeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Stanbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bouquillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nadaj-Pakleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.neurol.2026.04.007_bib0135","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.04.007_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/EB.S389629","article-title":"Ocular myasthenia gravis: a current overview","volume":"15","author":"Behbehani","year":"2023","journal-title":"Eye Brain"},{"issue":"2","key":"10.1016\/j.neurol.2026.04.007_bib0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.neurol.2026.04.007_bib0150","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","article-title":"Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification","volume":"36","author":"Wong","year":"2016","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.neurol.2026.04.007_bib0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.neurol.2026.04.007_bib0160","doi-asserted-by":"crossref","first-page":"e0274161","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neurol.2026.04.007_bib0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurol.2023.09.004","article-title":"Epidemiology of myasthenia gravis in France: a retrospective claims database study (STAMINA)","volume":"180","author":"Salort-Campana","year":"2024","journal-title":"Rev Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2026.04.007_bib0170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.neurol.2026.04.007_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.neurol.2026.04.007_bib0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis. 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.04.007_bib0185","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2026.04.007_bib0190","series-title":"Protocole national de diagnostic et de soins (PNDS)\u202f: myasth\u00e9nie autoimmune","year":"2015"},{"issue":"2","key":"10.1016\/j.neurol.2026.04.007_bib0195","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s13760-023-02187-0","article-title":"Current management of myasthenia gravis in Belgium: a single-center experience","volume":"123","author":"Mercelis","year":"2023","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"10.1016\/j.neurol.2026.04.007_bib0200","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","article-title":"Physician-reported perspectives on myasthenia gravis in the United States: a real-world survey","volume":"11","author":"Mahic","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurol.2026.04.007_bib0205","doi-asserted-by":"crossref","first-page":"553626","DOI":"10.3389\/fneur.2020.553626","article-title":"Determinants of quality of life in myasthenia gravis patients","volume":"11","author":"Szczudlik","year":"2020","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.04.007_bib0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1468-1331.2006.01149.x","article-title":"Correlation between regional myasthenic weakness and mental aspects of quality of life","volume":"13","author":"Rostedt","year":"2006","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2026.04.007_bib0215","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2147\/NDT.S3309","article-title":"Mycophenolate mofetil for myasthenia gravis: a clear and present controversy","volume":"4","author":"Heatwole","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.neurol.2026.04.007_bib0220","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neurol.2026.04.007_bib0225","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.04.007_bib0230","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231194821","article-title":"Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: what we learnt from consensus criteria in CIDP, myasthenia gravis and inflammatory myopathies","volume":"16","author":"Dalakas","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2026.04.007_bib0235","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.04.007_bib0240","doi-asserted-by":"crossref","first-page":"e70418","DOI":"10.1111\/ene.70418","article-title":"Rituximab in new-onset generalized myasthenia gravis: long-term follow-up of the RINOMAX clinical trial","volume":"32","author":"Wu","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2026.04.007_bib0245","doi-asserted-by":"crossref","first-page":"e2368","DOI":"10.1212\/WNL.0000000000200288","article-title":"Rituximab therapy in the treatment of juvenile myasthenia gravis: the French experience","volume":"98","author":"Molimard","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.04.007_bib0250","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.04.007_bib0255","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2026.04.007_bib0260","doi-asserted-by":"crossref","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T10:45:20Z","timestamp":1786877120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0035378726005291"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.007","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current management and treatment of patients with myasthenia gravis in France: A survey of the neurologist's perspective","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}